JAMPRO
27.4.2022 20:02:12 CEST | Business Wire | Press release
Brand Jamaica will be highlighted at the 126th staging of the Penn Relays, which will be held from April 28-30, 2022, in Philadelphia, Pennsylvania. Five Jamaican manufacturers, Annilu Limited, Herboo, King’s Jamaican Health and Wellness, Bresheh, and Shavuot International, will interact with buyers, distributors, and retailers to promote their products with the aim of increasing Jamaica’s export sales.
The trade mission is taking place as part of the export development programme Export Max III, which is led by JAMPRO, the Jamaica Business Development Corporation (JBDC), and the Jamaica Manufacturers and Exporters Association (JMEA). The event will highlight the island’s diverse manufacturing sector, and the products that are available for export.
Jamaica’s Prime Minister, The Most Honourable Andrew Holness, and Minister of Industry, Investment, and Commerce, Senator the Honourable Aubyn Hill, will attend the Penn Relays. The event will feature a pavilion designed to house the Jamaican companies that will facilitate engagement with the over 100,000 patrons that are expected to attend the event. B2B (Business-to-Business) meetings will also take place to support the companies during the trade mission, as they look to build meaningful business relationships in the United States.
“The Penn Relays are a great avenue for the promotion of Brand Jamaica because of its high profile as a major event and its historical connection with Jamaica, our athletes, and the diaspora, ” explained Minister Hill. “The event therefore provides an opportunity for Jamaica to not only display amazing athletic performances, but to connect with the Jamaican Diaspora expected to attend the event, and will introduce products to buyers and retailers in that area who are interested in securing ethnic food and other goods for their markets .”
The government is also encouraging Jamaicans abroad to invest in agro-processing, skills training, and in logistics, particularly Jamaica’s Special Economic Zones.
Penn Relays trade mission critical part of developing Jamaica’s exports
The mission will be a critical step in Jamaica’s ongoing efforts to identify new export opportunities for manufacturers, establish Jamaica as a supplier of high-quality products, and to increase the international exposure of the country’s exporters. It is one of the island’s major trade executions since the COVID-19 pandemic and is expected to give a boost to the Export Max participants.
Diane Edwards, President of JAMPRO said, “This particular event is expected to generate significant leads for our exporters, and should help them to secure contractual arrangements with targeted US distributors. While this will not be the first time that Jamaica has had major activities at the Penn Relays, I believe that there are advantages to this edition, as this will be the first staging of the competition since the onset of the COVID-19 pandemic. There is also a joyous mood surrounding the event, as it falls in the same year of Jamaica's 60th Anniversary as an independent nation .”
Edwards insisted that the event will reinforce Jamaica’s image as a source of high-quality exports, and will serve many purposes for the manufacturers, as well as buyers. She said, “The companies that will be at the Penn Relays represent the high quality and diversity of Jamaican products, and this initiative will give them the opportunity to be on the world stage and reach new audiences. For the buyers, it will introduce them to Jamaican exporters, and will show them the vast range of products that we have to offer. We believe that this mission will be fruitful for all the participants and stakeholders, and we look forward to seeing the positive impact it will have on the Jamaican economy.”
The Jamaica Promotions Corporation’s (JAMPRO’s) mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
